XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT,... XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia.
- Mechanism
- Curator reviewed
XL820 inhibits KIT as well as VEGFR2 and PDGFR, clinically validated targets implicated in a variety of human cancers. In tumor models of breast carcinoma, glioma and leukemia, the compound exhibited dose-dependent growth inhibition and has been shown to cause tumor regression. XL820 demonstrated excellent activity in target-specific cellular functional assays. In biochemical and cellular assays, XL820 potently inhibits mutant forms of KIT that confer resistance to approved KIT inhibitors. XL820 has good oral bioavailability and has shown sustained inhibition of target RTKs in vivo following a single oral dose.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Code names
- XL-820
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with XL820, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account